Declared Dividend • Jul 06
Dividend increased to NT$4.00 Dividend of NT$4.00 is 300% higher than last year. Ex-date: 20th July 2026 Payment date: 6th August 2026 Dividend yield will be 8.8%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. Reported Earnings • May 19
First quarter 2026 earnings released: NT$0.29 loss per share (vs NT$1.77 loss in 1Q 2025) First quarter 2026 results: NT$0.29 loss per share (improved from NT$1.77 loss in 1Q 2025). Revenue: NT$1.15b (flat on 1Q 2025). Net loss: NT$25.0m (loss narrowed 84% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Mar 12
Full year 2025 earnings released: NT$6.54 loss per share (vs NT$3.27 loss in FY 2024) Full year 2025 results: NT$6.54 loss per share (further deteriorated from NT$3.27 loss in FY 2024). Revenue: NT$4.60b (up 4.6% from FY 2024). Net loss: NT$567.4m (loss widened 100% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Mar 11
Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 23, 2026 Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 23, 2026. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city Taiwan Board Change • Feb 26
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Director Shui-Yung Lin was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Nov 13
Third quarter 2025 earnings released: NT$1.49 loss per share (vs NT$0.13 profit in 3Q 2024) Third quarter 2025 results: NT$1.49 loss per share (down from NT$0.13 profit in 3Q 2024). Revenue: NT$1.12b (up 4.5% from 3Q 2024). Net loss: NT$128.8m (down NT$140.2m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.53 loss per share (vs NT$0.81 loss in 2Q 2024) Second quarter 2025 results: NT$0.53 loss per share (improved from NT$0.81 loss in 2Q 2024). Revenue: NT$1.13b (up 3.7% from 2Q 2024). Net loss: NT$45.7m (loss narrowed 35% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Declared Dividend • Jun 23
Dividend of NT$1.00 announced Dividend of NT$1.00 is the same as last year. Ex-date: 7th July 2025 Payment date: 6th August 2025 Dividend yield will be 1.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Announcement • Jun 21
Orient Europharma Co., Ltd. Announces Cash Dividend, Payable on August 6, 2025 Orient EuroPharma Co., Ltd. announced the total amount of cash dividends is TWD 86,747,119 (TWD 1 per share). Ex-rights (Ex-dividend) date:2025/07/07. Ex-rights (Ex-dividend) record date:2025/07/13.
Payment date of cash dividend distribution:2025/08/06. Announcement • Jun 19
Orient EuroPharma Co., Ltd. Approves Board Changes Orient EuroPharma Co., Ltd. announced at annual general meeting held on June 18, 2025, the shareholders approved election of directors is as follows: Representative of TAIWAN EXCELSIOR CO., LTD.: Jinh-Hong, TSAI; Representative of TAIWAN EXCELSIOR CO., LTD.: Su-Fen, LIN; Representative of TAIWAN EXCELSIOR CO., LTD.: Mon-lin, TSAI. The list of newly elected independent directors is as follows: CHIH-CHENG, CHOU, SHUI-YUNG, LIN, CHING-HSIN, HSU and JIA-CING, PENG. Title and name of the previous position holder: Independent Director: Hua-Ming, LIN and Independent Director: PRAVEEN TYLE. Reported Earnings • May 14
First quarter 2025 earnings released: NT$1.77 loss per share (vs NT$1.04 loss in 1Q 2024) First quarter 2025 results: NT$1.77 loss per share (further deteriorated from NT$1.04 loss in 1Q 2024). Revenue: NT$1.16b (up 4.7% from 1Q 2024). Net loss: NT$153.7m (loss widened 71% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Announcement • May 06
Orient EuroPharma Co., Ltd. to Report Q1, 2025 Results on May 13, 2025 Orient EuroPharma Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025 Reported Earnings • Mar 13
Full year 2024 earnings released: NT$3.27 loss per share (vs NT$1.66 profit in FY 2023) Full year 2024 results: NT$3.27 loss per share (down from NT$1.66 profit in FY 2023). Revenue: NT$4.39b (down 4.4% from FY 2023). Net loss: NT$283.9m (down 297% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. New Risk • Mar 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.0% average weekly change). Large one-off items impacting financial results. Announcement • Feb 25
Orient EuroPharma Co., Ltd. to Report Fiscal Year 2024 Results on Feb 26, 2025 Orient EuroPharma Co., Ltd. announced that they will report fiscal year 2024 results on Feb 26, 2025 Reported Earnings • Nov 19
Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.40 loss in 3Q 2023) Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.40 loss in 3Q 2023). Revenue: NT$1.07b (down 2.5% from 3Q 2023). Net income: NT$11.4m (up NT$46.1m from 3Q 2023). Profit margin: 1.1% (up from net loss in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
Second quarter 2024 earnings released: NT$0.81 loss per share (vs NT$2.18 loss in 2Q 2023) Second quarter 2024 results: NT$0.81 loss per share (improved from NT$2.18 loss in 2Q 2023). Revenue: NT$1.09b (down 4.1% from 2Q 2023). Net loss: NT$70.5m (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Upcoming Dividend • Jul 12
Upcoming dividend of NT$1.00 per share Eligible shareholders must have bought the stock before 19 July 2024. Payment date: 15 August 2024. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.0%). Reported Earnings • May 19
First quarter 2024 earnings released: NT$1.04 loss per share (vs NT$0.32 profit in 1Q 2023) First quarter 2024 results: NT$1.04 loss per share (down from NT$0.32 profit in 1Q 2023). Revenue: NT$1.10b (down 4.0% from 1Q 2023). Net loss: NT$89.9m (down 423% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • May 03
Orient EuroPharma Co., Ltd. to Report Q1, 2024 Results on May 10, 2024 Orient EuroPharma Co., Ltd. announced that they will report Q1, 2024 results on May 10, 2024 New Risk • Mar 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 1,087% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Earnings have declined by 55% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Mar 05
Full year 2023 earnings released: EPS: NT$1.66 (vs NT$3.58 loss in FY 2022) Full year 2023 results: EPS: NT$1.66 (up from NT$3.58 loss in FY 2022). Revenue: NT$4.59b (down 2.9% from FY 2022). Net income: NT$143.9m (up NT$454.7m from FY 2022). Profit margin: 3.1% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Announcement • Feb 23
Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 20, 2024 Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: 13F- Taiwan Conference Room No.128, Sec. 6, Chengde Rd., Beitou Dist. Taipei City Taiwan Agenda: To consider business Report for Year 2023; to discuss supervisors Review Report on the 2023 Financial Statements; to discuss report on the Distribution of Directors & Supervisors and Employees Remuneration for Year 2023; and to discuss other matters. New Risk • Aug 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.12b market cap, or US$97.8m). Reported Earnings • Aug 13
Second quarter 2023 earnings released: NT$2.18 loss per share (vs NT$1.12 loss in 2Q 2022) Second quarter 2023 results: NT$2.18 loss per share (further deteriorated from NT$1.12 loss in 2Q 2022). Revenue: NT$1.13b (down 5.8% from 2Q 2022). Net loss: NT$189.0m (loss widened 94% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance. Announcement • Aug 11
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Accounting Officer Orient EuroPharma Co., Ltd. appointed Jack Wang, Finance Manager, FETC/Section Chief, Far Eastern New Century Corp./Assistant Manager, Deloitte & Touche as Accounting Officer, effective August 10, 2023. Announcement • Aug 02
Orient EuroPharma Co., Ltd. Announces Change in the Financial Officer Orient EuroPharma Co., Ltd. appointed GJack Wang Resume, Finance Manager, FETC/Section Chief, Far Eastern New Century Corp. /Assistant Manager, Deloitte & Touche as Financial Officer in place of Phoebe Lee, effective August 1, 2023. Reported Earnings • Mar 09
Full year 2022 earnings released: NT$3.58 loss per share (vs NT$1.39 profit in FY 2021) Full year 2022 results: NT$3.58 loss per share (down from NT$1.39 profit in FY 2021). Revenue: NT$4.73b (flat on FY 2021). Net loss: NT$310.8m (down 359% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2022 earnings released: NT$2.16 loss per share (vs NT$0.54 loss in 3Q 2021) Third quarter 2022 results: NT$2.16 loss per share (further deteriorated from NT$0.54 loss in 3Q 2021). Revenue: NT$1.10b (down 3.5% from 3Q 2021). Net loss: NT$187.5m (loss widened 298% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improved over the past week After last week's 17% share price gain to NT$40.15, the stock trades at a trailing P/E ratio of 73.6x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 22% over the past three years. Reported Earnings • Aug 13
Second quarter 2022 earnings released: NT$1.12 loss per share (vs NT$0.076 loss in 2Q 2021) Second quarter 2022 results: NT$1.12 loss per share (down from NT$0.076 loss in 2Q 2021). Revenue: NT$1.20b (up 6.3% from 2Q 2021). Net loss: NT$97.3m (loss widened NT$90.6m from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jul 11
Upcoming dividend of NT$0.85 per share Eligible shareholders must have bought the stock before 18 July 2022. Payment date: 05 August 2022. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Taiwanese dividend payers (6.7%). Lower than average of industry peers (2.9%). Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: NT$0.27 (up from NT$0.066 in 1Q 2021). Revenue: NT$1.14b (down 5.9% from 1Q 2021). Net income: NT$23.5m (up 309% from 1Q 2021). Profit margin: 2.1% (up from 0.5% in 1Q 2021). Revenue missed analyst estimates by 29%. Earnings per share (EPS) also missed analyst estimates by 126%. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 06
Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 30, 2022 Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 30, 2022. Reported Earnings • Feb 28
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: NT$1.39 (down from NT$2.30 in FY 2020). Revenue: NT$4.77b (down 12% from FY 2020). Net income: NT$120.2m (down 40% from FY 2020). Profit margin: 2.5% (down from 3.7% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 29%. Earnings per share (EPS) also missed analyst estimates by 126%. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 15
Third quarter 2021 earnings released: NT$0.54 loss per share (vs NT$0.15 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: NT$1.14b (down 2.4% from 3Q 2020). Net loss: NT$47.1m (loss widened 252% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 07
Upcoming dividend of NT$1.50 per share Eligible shareholders must have bought the stock before 14 September 2021. Payment date: 30 September 2021. Trailing yield: 3.7%. Lower than top quartile of Taiwanese dividend payers (5.2%). Higher than average of industry peers (2.3%). Reported Earnings • Aug 13
Second quarter 2021 earnings released: NT$0.08 loss per share (vs NT$1.48 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: NT$1.13b (down 16% from 2Q 2020). Net loss: NT$6.62m (down 105% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • May 14
First quarter 2021 earnings released: EPS NT$0.07 (vs NT$1.36 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$1.21b (down 22% from 1Q 2020). Net income: NT$5.76m (down 95% from 1Q 2020). Profit margin: 0.5% (down from 7.6% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 16% per year. Announcement • Mar 03
Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 28, 2021 Orient EuroPharma Co., Ltd., Annual General Meeting, Jun 28, 2021. Is New 90 Day High Low • Mar 03
New 90-day low: NT$45.80 The company is down 8.0% from its price of NT$50.00 on 03 December 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Reported Earnings • Feb 27
Full year 2020 earnings released: EPS NT$2.30 (vs NT$2.86 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$5.38b (down 12% from FY 2019). Net income: NT$199.3m (down 20% from FY 2019). Profit margin: 3.7% (down from 4.1% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 15% per year. Is New 90 Day High Low • Feb 04
New 90-day low: NT$45.95 The company is down 10.0% from its price of NT$51.30 on 06 November 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 17% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: NT$47.00 The company is down 10.0% from its price of NT$52.20 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: NT$48.65 The company is down 2.0% from its price of NT$49.60 on 25 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period. Announcement • Dec 16
Regent Pacific's Commercial Strategic Partner Receives Approval from Taiwan Food and Drug Administration Regent Pacific Group Limited announced that Orient EuroPharma Co. Ltd. the Group's commercial strategic partner for Taiwan, Hong Kong, Macau and some other countries and regions in South East Asia has received the marketing authorisation approval for Taiwan from the Taiwan Food and Drug Administration. This is the final regulatory approval process required for the marketing, distribution and sale of Fortacin, a solution to premature ejaculation, in Taiwan. Pursuant to the licence agreement with Orient EuroPharma, Regent Pacific will receive a payment of $300,000 from Orient EuroPharma. Is New 90 Day High Low • Dec 08
New 90-day low: NT$49.30 The company is down 8.0% from its price of NT$53.40 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 11% over the same period. Reported Earnings • Nov 18
Third quarter 2020 earnings released: NT$0.15 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: NT$1.17b (down 21% from 3Q 2019). Net loss: NT$13.4m (down 143% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.15 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: NT$1.17b (down 21% from 3Q 2019). Net loss: NT$13.4m (down 143% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Sep 25
New 90-day low: NT$49.60 The company is down 2.0% from its price of NT$50.40 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. 
